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Oliveira L, Costa-Neto CM, Nakaie CR, Schreier S, Shimuta SI, Paiva ACM. The Angiotensin II AT1 Recep-
tor Structure-Activity Correlations in the Light of Rhodopsin Structure. Physiol Rev 87: 565–592, 2007;
10.1152/physrev.00040.2005.—The most prevalent physiological effects of ANG II, the main product of the renin-
angiotensin system, are mediated by the AT1 receptor, a rhodopsin-like AGPCR. Numerous studies of the cardio-
vascular effects of synthetic peptide analogs allowed a detailed mapping of ANG II’s structural requirements for
receptor binding and activation, which were complemented by site-directed mutagenesis studies on the AT1 receptor
to investigate the role of its structure in ligand binding, signal transduction, phosphorylation, binding to arrestins,
internalization, desensitization, tachyphylaxis, and other properties. The knowledge of the high-resolution structure
of rhodopsin allowed homology modeling of the AT1 receptor. The models thus built and mutagenesis data indicate
that physiological (agonist binding) or constitutive (mutated receptor) activation may involve different degrees of
expansion of the receptor’s central cavity. Residues in ANG II structure seem to control these conformational
changes and to dictate the type of cytosolic event elicited during the activation. 1) Agonist aromatic residues (Phe8
and Tyr4) favor the coupling to G protein, and 2) absence of these residues can favor a mechanism leading directly
to receptor internalization via phosphorylation by specific kinases of the receptor’s COOH-terminal Ser and Thr
residues, arrestin binding, and clathrin-dependent coated-pit vesicles. On the other hand, the NH2-terminal residues
of the agonists ANG II and [Sar1]-ANG II were found to bind by two distinct modes to the AT1 receptor extracellular
site flanked by the COOH-terminal segments of the EC-3 loop and the NH2-terminal domain. Since the [Sar
1]-ligand
is the most potent molecule to trigger tachyphylaxis in AT1 receptors, it was suggested that its corresponding binding
mode might be associated with this special condition of receptors.
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I. INTRODUCTION
A. The Renin-Angiotensin System
The renin-angiotensin system (Fig. 1) regulates blood
pressure and fluid homeostasis (227) by renin-mediated
hydrolysis of angiotensinogen to release ANG I. This in-
active decapeptide is further hydrolyzed by the angioten-
sin converting enzyme (ACE) yielding the vasoconstrictor
octapeptide ANG II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe), the
classical effector of the renin-angiotensin cascade. ANG I
may also be hydrolyzed by prolyl-endopeptidase and car-
boxypeptidases to yield the vasodilator heptapeptide
ANG-(1–7). Alternatively, ACE-2, a carboxypeptidase ho-
molog of ACE (46, 285), cleaves a single residue from
ANG I to generate ANG-(1–9), which can be hydrolyzed by
ACE to yield ANG-(1–7) (Fig. 1). Degradation products of
ANG II lacking the NH2-terminal Asp (ANG III) and the
Asp-Arg (ANG IV) residues are particularly involved in
brain and pituitary physiology (10, 300).
In addition to the regulation of blood pressure, sev-
eral other functions have been described for ANG II,
leading to the discovery of different receptors in different
tissues (43), most of them belonging to the superfamily of
G protein-coupled receptors (GPCRs). ANG III shares the
same receptors and exerts similar effects as ANG II in the
brain, where both peptides have equivalent biological
potencies to increase blood pressure; however, because
ANG II is converted in vivo to ANG III, the identity of the
true effector is unknown. ANG IV enhances learning and
memory in rodents and was shown to bind to a specific
receptor, known as the AT4 receptor, identified as the
transmembrane insulin-regulated membrane aminopepti-
dase (IRAP), which is not a GPCR (5). However, although
it is inactive on the basal state of the ANG II AT1 receptor,
ANG IV is a full agonist of constitutively activated recep-
tor mutants (145).
Two ANG II receptor types (AT1 and AT2) were
cloned and sequenced (125, 186, 187, 251), both belonging
to the rhodopsin-like family (family A) of GPCRs (AGPCR).
ANG-(1–7) was reported to interact with a different GPCR,
the mas protooncogene product (250), exerting vasodilator
and antiproliferative effects (58, 59).
AT1 and AT2 receptor types can be distinguished by
their binding profiles to different ligands. Thus, whereas
the AT1 receptor has a high affinity for the nonpeptide
antagonist losartan (284), AT2 binds preferentially to the
peptide antagonist CGP42112 (283). The two receptor
types trigger distinct (sometimes opposing) signal trans-
duction pathways (113) such as effects leading to growth
and antigrowth responses (91, 92). The idea that the AT2
receptor is an AT1 receptor antagonist is also suggested
by a finding not yet confirmed by others, that the AT1/AT2
receptor heterodimer inhibits AT1 signals (2).
AT1 and AT2 receptors also differ in that the former
undergoes rapid internalization and desensitization upon
agonist stimulation (97, 281), whereas the AT2 receptor
does not internalize and is not desensitized upon interac-
tion with the agonist (87, 108, 186, 288). However, con-
trasting with these findings, AT2 receptor was shown to
be internalized in response to ANG II and driven to play a
novel signaling pathway. This consists of a receptor-me-
diated translocation of a cytosolic transcription factor,
the promyelocytic zinc finger protein (PLZF), to the nu-
cleus and activation of p85alfaPI3K and p70S6 kinase lead-
ing to an increase of protein synthesis (256).
AT2 receptors have also been shown to play a role in
a number of biological processes, such as vascular relax-
ation, antiproliferation, cellular differentiation, and apo-
ptosis (32, 68, 98, 271), but it is the AT1 receptor that plays
a critical role in signaling pathways that mediate most of
the classical physiological and pathological effects of
ANG II on target cells, such as vascular smooth muscle
cell contraction, aldosterone release, stimulation of sym-
pathetic transmission and cellular growth, salt appetite,
thirst, sympathetic outflow, and inhibition of renin bio-
synthesis and secretion (9, 43, 63, 267, 282). Interestingly,
each of these ANG II-induced effects is triggered at dif-
ferent time intervals: seconds in cell signaling, activation
of phospholipase C, generation of inositol phosphate (IP)
and Ca2 release; minutes in mitogen-activated protein
kinase activation; hours in activation of Janus kinase
(JNK), signal transducers, and activators of transcription
pathway (79).
The AT1 receptor acts by stimulating protein Gq/G11
and subsequently phospholipase C and IP production or
by regulating the level of cAMP by activation of protein Gi
(12, 173, 260). In addition to vasoconstriction, regulation
FIG. 1. Renin-angiotensin cascade showing various hydrolytic steps
from angiotensinogen to angiotensin-like peptides. ACE, angiotensin
converting enzyme; ACE2, ACE-like carboxypeptidase; PEP, prolyl-en-
dopeptidase. Peptide amino acid residues are represented by the one-
letter code.
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of renal tubular electrolyte handling, aldosterone release,
and facilitation of adrenergic release, the AT1 receptor is
one of the most potent stimulators of hypertrophic re-
modeling of the vascular walls, through ANG II-mediated
growth-promoting signals. It has been suggested that the
intracellular signaling mechanisms by which the AT1 re-
ceptor exerts hypertrophic and/or hyperplastic effects on
targets such as vascular smooth muscle cells are closely
associated with receptor and nonreceptor tyrosine ki-
nases (49). Furthermore, it has been demonstrated that
G12/G13 can induce vascular smooth muscle cell contrac-
tion through a Rho/Rho-kinase (ROCK)-mediated path-
way (71). These authors provided evidence that receptor
AT1 couples with Gq and G12 chains to efficiently induce
cell contraction via dual regulation of the myosin light
chain (MLC) phosphorylation: the Ca2-dependent stim-
ulation of MLC kinase and the Ca2-independent Rho/
ROCK-mediated inhibition of myosin phosphatase.
ANG II-stimulated activation of some mitogen-acti-
vated protein kinases (MAPKs) has been reported (74,
76), with calcium channels being essential in this mecha-
nism. In fact, activation of the extracellular signal-regu-
lated kinase (ERK1/ERK2), tyrosine kinase 2, and Janus-
activated kinase 2 (Jak2), as well as phosphorylation of
signal transducer and activator of transcription (STAT1
and STAT3), were shown to be inhibited by the calcium
channel blocker azelnidipine (152).
Superoxide generation has been found to be medi-
ated by ANG II and to play an important role in vascular
smooth muscle cell growth, contraction/relaxation, and
inflammation. It was shown that ANG II-induced oxidant
activity is increased and generation of reactive oxygen
species is enhanced in conditions associated with vascu-
lar damage such as in hypertension, ischemia-reperfusion
injury, atherosclerosis, and diabetes (30, 49).
AT1 receptors desensitize following agonist stimula-
tion due to sequestration and endocytosis (281). Differ-
ently from this desensitization, acute loss of response
upon repeated treatments with ANG II is also observed in
smooth muscle cells, characterizing the event of tachy-
phylaxis (130, 216, 270).
Homodimerization has been described for AT1 recep-
tors linked to the action of factor XIIIA transglutaminase
(3) or as a natural phenomenon occurring in wild-type
receptors (233). However, experiments demonstrating oli-
gomerization (or at least cross-talking) in AT1 receptors
consisted of coexpression of a wild-type and a nonfunc-
tional mutant (85, 183). Heterodimerization of AT1 recep-
tor with AT2 (2) and bradykinin B2 (1) receptors, and
other AGPCRs such 2-adrenergic receptors (19), has
been claimed to occur. Interestingly, it appears that the
dimerization of AT2 receptors might be regulated by di-
sulfide bond exchange (179).
B. Scope of This Review
The ANG II AT1 receptor is responsible for virtually
all of the known peripheral actions of ANG II. It has been
most extensively studied by site-directed mutagenesis
aiming at the elucidation of ligand binding, signal trans-
duction, phosphorylation, binding to arrestins, internal-
ization, desensitization, tachyphylaxis, and other proper-
ties. The main scope of this review is to correlate the AT1
receptor basic functions (ANG II binding, receptor acti-
vation, signal transduction across the transmembrane
structure, and some events at the cytosolic ends of the
receptor) with the data available about AGPCR se-
quences, rhodopsin structure, and mechanism of receptor
action. Presentation and discussion of related events such
as G protein coupling, arrestin binding, desensitization,
and tachyphylaxis shall not be fully comprehensive but
limited to features considered necessary to enrich the
main subject. Other events such as oligo(di)merization of
AGPCRs, for which no relationship with receptor activa-
tion has been completely confirmed, shall not be dis-
cussed.
II. ANGIOTENSIN II STRUCTURE-ACTIVITY
RELATIONSHIPS
A. Receptor Binding and Activation
Long before cloning of the receptors was achieved,
numerous studies of the cardiovascular effects of syn-
thetic peptide analogs allowed a detailed mapping of ANG
II’s structural requirements for receptor binding and ac-
tivation (130, 131, 212, 213, 215). These structural require-
ments can be assumed to apply to the AT1 receptor, since
the biological responses that were analyzed in those early
reports were later found to be mediated by that receptor
type.
Analyses of the effects of different ANG II analogs
bearing single or multiple modifications indicated that an
electrostatic interaction between the ANG II COOH-ter-
minal carboxylate group and the receptor is an important
factor for high-affinity binding (100) and that the peptide’s
Arg2, Tyr4, and His6 side chains are also important for
high-affinity binding (31, 178, 239, 240). On the other hand,
replacements of Tyr4 and mainly Phe8 by aliphatic resi-
dues were shown to generate competitive antagonists,
thus attesting to the importance of these aromatic resi-
dues for receptor activation (70, 247). The Val3, Ile5, and
Pro7 residues were found to be neither crucial for binding
nor for activation. Asp1 was not found to be relevant,
since analogs with replacements in this position, as well
as des-Asp1-ANG II (ANG III), still retain significant activ-
ity. On the other hand, the introduction of a sarcosine
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(Sar) residue in position 1 increased the potencies of
agonist and antagonist analogs (26, 81, 211, 238, 239).
Pharmacological (158) and mutagenesis (249) studies on
the AT1 receptor indicated that [Sar
1]-ANG II has a bind-
ing mode different from that of the natural agonist, as
discussed in section III, B4 and D1. Also, the presence of
Sar in position 1 seems to induce a reaccommodation of
other residues involved in binding, such as Arg2 (249).
ANG II was shown to be in a random conformation in
aqueous solution, various conformers coexisting in equi-
librium, which would be displaced towards the “active
one” upon binding to the receptor (217). One of these
conformers could be that of a horseshoe-shaped structure
of ANG II described in a complex of the peptide with
antibody (67). Other studies were published in which
different conformations were proposed for ANG II or
synthetic peptide analogs in aqueous or other media (57,
163, 194, 236), but no rational information was obtained
about the “active conformation” that binds to the recep-
tor. Other approaches were based on constraints intro-
duced in the ANG II structure so as to freeze certain
conformations of the peptide, thus allowing their biolog-
ical activities to be checked (122, 192, 306). However,
despite the great deal of effort, no conclusive results
leading to knowledge about the active conformation of
ANG II could be obtained using these approaches.
B. Antagonism by ANG II Analogs
As expected from the structural determinants for
signaling described above, one of the first reported antag-
onists for ANG II was [Phe4,Tyr8]-ANG II (164), and in the
following years, other antagonists were reported, mostly
bearing modifications in the Phe8 position and usually
also with sarcosine in place of Asp1. A milestone in such
studies was the discovery of the analog saralasin
([Sar1,Ala8]-ANG II) as the first high-affinity antagonist
(222).
During the first years of investigations on this sub-
ject, development of antagonists with modifications at the
Tyr4 position was less explored, possibly due to the lower
potency observed in the first analogs with modifications
in this position (246). Later on, sarmesin, a potent antag-
onist with hydroxymethylated Tyr4 ([Sar1,Tyr(Me)4]-ANG
II), was described (252). Combined modifications on both
Tyr4 and Phe8 were shown to be nonadditive, generating
antagonists of lower potencies (70, 247).
C. Desensitization and Tachyphylaxis
It has been demonstrated in whole animals, isolated
tissues, and cultured cells that the AT1 receptor may be
inactivated when left in prolonged contact with the ago-
nist (96, 130, 184, 216, 218, 226, 270, 281). This loss of
response has been linked to two mechanisms, tachyphy-
laxis and desensitization, which were first recognized by
the experimental protocols used to elicit them. Tachyphy-
laxis is triggered by cycles of stimulation (agonist addi-
tion and washing) that have to be repeated twice, thrice,
and more times to abolish the response (216, 270). De-
sensitization is promoted by prolonged contact of recep-
tor with a same dose of agonist.
Differently from desensitization, tachyphylaxis
seems to act at the level of agonist-receptor interaction
and is dependent on the NH2-terminal ammonium group
and the Arg2 guanidinium group of ANG II. [Succinyl1]-
ANG II does not induce and [Sar1]-ANG II induces an
enhanced tachyphylactic phenomenon (211), with this
effect being explained by the increased protonation of the
sarcosine secondary amino group at physiological pH
(214, 216). The importance of the Arg2 guanidinium group
for tachyphylaxis triggering has also been supported by
the fact that [Lys2]-ANG II and even [Sar1,Lys2]-ANG II
cannot induce tachyphylaxis (169, 211). Also differing
from desensitization, tachyphylaxis induction depends on
the aromatic ring at position 4 of ANG II, but some
apparently conflicting aspects need to be analyzed. The
phenolic hydroxyl of Tyr4 is vital to elicit in vitro tachy-
phylaxis, a property that is lost with [Phe4]-ANG II (185,
262). However, paradoxically, this ANG II analog is able
to trigger tachyphylaxis in vivo (286), a condition that was
not described for wild-type ANG II.
Thus tachyphylaxis is possibly due to conformational
changes on the ANG II-AT1 receptor complex (126, 216,
263, 264, 270), a supposition compatible with findings
showing that this phenomenon can be prevented or re-
versed by the AT1 receptor antagonist losartan (241).
Desensitization has been shown to be correlated with
phosphorylation of Ser and Thr residues in the cytosolic
domains of AT1 receptor (104, 281). Therefore, rapid de-
sensitization involves primarily phosphorylation (27) of
the receptor through two distinct types of Ser/Thr protein
kinases: the second messenger-activated kinases, protein
kinase A or C (75, 127, 245, 275), and the second messen-
ger-independent G protein-coupled receptor kinases
(110).
The installation of both tachyphylaxis and desensiti-
zation in AT1 receptors leads to decays of IP formation
and calcium influx (4, 126, 264), but the most flagrant
difference between these two states is that only tachyphy-
laxis is accompanied by reduction of sodium influx (4,
264).
AT1 receptor sequestration and internalization have
been involved in ANG II desensitization in smooth muscle
cells (6, 75, 76, 289). However, no results could be ob-
tained from a series of studies supporting this correlation
(23, 97, 102, 202, 280). Hence, sequestration does not
appear to play a major role in desensitization but may
instead be involved in the resensitization process (79).
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III. AT1 RECEPTOR STRUCTURE-ACTIVITY
CORRELATIONS
A. Receptor Structure
1. Sequences of AGPCRs
Using the rhodopsin structure (151, 221) as a tem-
plate, one may define the topography of the AGPCR se-
quence segments relative to the plasma membrane (Fig.
2) starting at the extracellular (Nt domain) and ending at
the cytosolic side (Ct domain). Between these two ex-
tremes there is a seven-transmembrane (7TM) bundle
(helices I–VII) intercalated by three intracellular loops
(IC-1, IC-2, and IC-3) and three extracellular loops (EC-1,
EC-2, and EC-3).
Multiple sequence alignment was performed for
2,800 AGPCRs according to the rhodopsin structure and
oriented by very conserved residues in the 7TM helices
and adjoining domains which were found without dele-
tion or insertion in many receptors of the family (see
Table A in the supplemental material1 and the consensual
segments of sequences in Figs. 2 and 3) (13, 207, 209).
Despite these conserved residues, true fingerprints which
discriminate family A from other GPCR families, AGPCRs
are heterogeneous because they belong to different
classes of receptors, containing specific motifs inserted in
the loops and terminal domains. However, within recep-
tor types and subtypes, there is a remarkable similarity
regarding both residues and lengths of the various seg-
ments (see GPCRDB).
Therefore, AT1 and AT2 ANG II receptor types were
included in the AGPCR family and are easily identified by
multiple sequence alignment (see GPCRDB and Table B in
the supplemental material) (Fig. 3). However, the effi-
ciency of this procedure for characterizing the AT1A,
AT1B, and other subtypes (114, 143) is subject to ques-
tions (see Table C and the text of the supplemental ma-
terial for more details).
To allow a comparison of the different GPCR se-
quences, residue positions shall be identified using the
general GPCRDB numbering system (99). In this system,
the numbers for positions in the 7TM bundle have three
digits, the first being the number of the helix (1–7) and the
remaining two being the number of the position relative to
the reference positions (Fig. 2).
The same method was applied to number positions of
extramembrane domains that are conserved for some
classes of receptors, as indicated in Figure 2 for the EC-1
and EC-2 loops of a large majority of nonolfactory
AGPCRs and for the EC-3 loop of ANG II, bradykinin,
endothelin, and other receptors (41; see GPCRDB). In
receptor domains devoid of conserved motifs (for in-
stance, the IC-1 and IC-3 loops), the respective sequences
were divided into two halves (N and C) that were num-
bered according to the references used in the adjoining
helices. As an example, Table 1 shows the segments of an
AT1 receptor sequence (AG1R_RAT: Refs. 115, 187) with
the respective natural and general GPCRDB numbers.
Residue positions used as references for numbering are1The online version of this article has supplemental data.
FIG. 2. Schematic representation of the AGPCR
7-transmembrane (7TM) bundle structure, adjacent
loops, and domains. TM helices I-VII and cytosolic helix
VIII are indicated; ECs and ICs are extracellular and
cytosolic loops, respectively. Segments of sequences
consensual to all AGPCRs are shown in black; EC-1 and
EC-2 loops found in the large majority of nonolfactory
AGPCRs are shown in blue; insertions, including a sec-
ond extracellular disulfide bond found in ANG II, bra-
dykinin, endothelin, and other receptors, are shown in
red. Amino acid residues are represented by the one-
letter code, and conserved positions used as references
for alignment are indicated with the respective general
numbers in parentheses.
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indicated. In the text, for every position of the AT1 recep-
tor (or of other classes of AGPCRs), the numbering sys-
tem is indicated as shown in Table 1: first the natural
number (1–3 digits) followed by superscript A (AT1 re-
ceptor), superscript R (rhodopsin), and superscript G
(other AGPCRs), and then the respective general
GPCRDB numbers (3 digits) in parentheses.
2. Rhodopsin structure
The ground or inactive structure of bovine rhodopsin
(151, 221) consists of a 7TM bundle surrounding an ellip-
soidal central cavity whose major axis is aligned with
helices I-III and V-VII (Fig. 4). The broader side of this
cavity is flanked by helices II-III and VI-VII, and the nar-
rower sides are closed by helices I and V. The cavity is
accessible from the intracellular side despite the exis-
tence of interactions between the cytosolic ends of heli-
ces II, III, and V-VII. The extracellular side is closed by the
EC-2 loop hairpin that lies inside the central cavity paral-
lel to the membrane surface, making interactions with
FIG. 3. Sequences of rhodopsin (Rhod) and AT1 receptors. The
segments are identified by the same colors as in Fig. 2. GN, general
numbering for AGPCRs (shown in parentheses in the text); the numbers
for sequences of rhodopsin and AT1 receptor are in the lines below the
respective sequences; *positions used as references to align the consen-
sual segments of the sequences. The insertion of 8–10 residues observed
in the EC-3 loops of AT1 receptors and other AGPCRs (AT2, bradykinin,
endothelin, purine, Cys-leukotriene) contains a conserved Cys274(650),
supposedly making a second disulfide bond with an Nt conserved
Cys18AA(100) (41).
TABLE 1. The GPCRDB numbering sytem applied to
7-transmembrane and extramembrane regions
of AT1 receptor sequences
Region References
Segment of Sequence
AG2_RAT GPCRDB
Nt Cys
18A(100) –25 –107
Helix I Asn46A(130) 26–53 110–137
IC-1 loop (N) Asn46A(130) 54–58 138–142
IC-1 loop (C) Leu70A(220)Asp74A(224) 59–61 209–211
Helix II Leu70A(220)Asp74A(224) 62–91 212–241
EC-1 loop (N) Trp94A(270) 92–94 268–270
EC-1 loop (C) Gly97A(311) 95–97 309–311
Helix III Arg126A(340) 98–130 312–344
IC-2 loop Pro133A(348) 131–134 346–359
Helix IV Trp153A(420) 145–164 412–431
EC-2 loop Cys100A(470) 165–192 455–482
Helix V Pro207A(520) Tyr215A(528) 193–218 506–531
IC-3 loop (N) Pro207A(520) Tyr215A(528) 219–226 532–539
IC-3 loop (C) Pro255A(620) Trp253A(618)
Phe249A(614)
227–234 592–599
Helix VI Pro255A(620) Trp253A(618)
Phe249A(614)
235–264 600–629
EC-3 loop (N) Pro255A(620) Trp253A(618)
Phe249A(614)
265–267 630–632
EC-3 loop (Ins) Cys274A(650) 268–275 644–651
EC-3 loop (C) Pro299A(730) 276–280 707–711
Helix VII Pro299A(730) 281–301 712–732
VII–VIII bend Tyr302A(734) 302–306 734–738
Helix VIII Phe309A(810) 307–320 808–821
Ct Phe
309A(810) 321– 822–
See Figures 1 and 2 for identification and text for definitions.
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side chains of helices. A remarkable interaction in rho-
dopsin is a disulfide bridge [Cys110R(315)-Cys187R(470)] be-
tween EC-2 and the top of helix III (Figs. 2 and 3), which
is found in a majority of AGPCRs. Following the end of
helix VII, the main chain forms a 90° bend and then a
cytosolic helix (helix VIII) running parallel to the mem-
brane. This helix, whose relative position was claimed to
be due to crystal contacts, is tied to helix VII, to the
VII-VIII bend, and to helices I and II by side chain inter-
actions such as that involving Tyr306R(734) and Phe313R(810)
(151) (Figs. 2 and 3).
3. Patterns of residue conservation
Patterns of residue conservation have previously
been determined (209) on residue positions of AGPCR
aligned sequences (see supplemental material Table A).
For each position of the alignment, values of entropy (E)
and variability (V) were determined and distributed along
an E-V plot (Fig. 5; see legend of this figure for definitions
of E and V). Over a broad range of values, it was possible
to separate the positions of the sequence alignment ac-
cording to levels of residue conservation by grouping
them into boxes 11, 12, 22, 23, and 33, according to
different ranges of E and V values.
When the residue positions of EV boxes were
mapped in the rhodopsin structure, an oriented distribu-
tion was observed (Fig. 6): 1) the most conserved posi-
tions of boxes 11, 12, and 22 are at the cytosolic half of the
7TM bundle central cavity; 2) the positions of boxes 12,
22, and 23 with intermediate E and V values are at the
middle of the 7TM bundle central cavity; 3) variable po-
sitions of box 23 are in the extracellular half of the central
cavity and on the external wall of the 7TM bundle struc-
ture forming an interface with the membrane bilayer; and
4) the most variable positions of box 33 are at the extra-
cellular and cytosolic limits of the 7TM bundle.
Applied to well-known protein families, such as glo-
bins, ras-like proteins, and serine-proteases (208), EV
analysis allowed us to relate function to the structure of
these molecules: 1) the more conserved positions are
mostly at accessible regions of the structures forming a
common main site, heme site in globins, nucleotide site in
ras-like chains, and catalytic site in serine-proteases; 2)
the more variable positions are mostly at the surface of
the structures forming modulator sites, specific for each
protein type and subtype; and 3) the positions of boxes
12, 22, and 23 are in the core of the proteins involved in
structure-stabilizing or signal-transduction roles.
This structure-function map obtained from known
proteins may be extrapolated to AGPCRs in general, what
allowed us to assume that the conserved positions of
these receptors (EV boxes 11 and 12 in Fig. 5) form a
common main site and the variable positions (boxes 23
and 33 in Fig. 5) form modulator sites. The main site is at
the cytosolic side of the 7TM bundle central cavity and
may be related to a common cluster of conserved polar
residues consisting of Asn(130), Asp(224), Asp(339), Arg(340),
Asn(729), and Tyr(734) (see Fig. 3) which includes a part of
a sodium allosteric site for some AGPCR classes (191)
(see sect. IIID2). The most important modulator site (the
FIG. 5. Entropy/variability plot calculated for residue positions in
multiple sequence alignment of 2,800 AGPCRs. Variability (V) is the
number of different residues (1–20) found at each position. Entropy (E)
(0.0–3.0) is given by the equation E  ¥(i  1–20)fi(lnfi), where fi is
the fraction of each amino acid found at each position. In the numbers
designating boxes 11, 12, 22, 23, and 33, the first and second digits
express increasing ranges of V and E values, respectively. Thus 11 and
33 are boxes containing highly conserved and highly variable residue
positions, respectively.
FIG. 4. Longitudinal (A) and cross-section (B) views of rhodopsin’s
7TM bundle structure. The helix pairs II and III (gold) and VI and VII
(green) form the broader walls of the ellipsoidal central cavity. Helices
I and V (red) form the other sides of the cavity. Helix IV is shown in light
blue, and retinal is shown in magenta.
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agonist site) is at the extracellular side of the 7TM bundle
central cavity (29, 205) (Fig. 6) and corresponds to the
retinal site in rhodopsin structure (221). Positions with
intermediate E and V values in the alignment of all
AGPCR sequences are in the core of the 7TM structure,
between the two sites. Thus, in the course of receptor
activation, a signal may be transmitted from one site to
the other through positions with intermediate EV values
(209).
Additional experimental evidence suggests the exis-
tence of other modulator sites (variable positions) in
other regions of the AGPCR structure, such as the COOH-
terminal end of helix III [including the Tyr(339) residue of
the DRY motif], the cytosolic ends of helices V and VI and
adjacent sequences of the loop between these helices,
helix VIII, and the VII-VIII bend (see references in supple-
mental material Table D).
4. The AT1 receptor
Despite the low level of residue identity (20% in
relation to rhodopsin), AT1 receptors can be modeled
(203) in homology to rhodopsin structure (151, 221), at
least at the level of sequence segments containing con-
served residues (Fig. 7). Details and the rationale support-
ing this procedure are described in the supplemental ma-
terial.
A model of inactive AT1 receptor was built by homol-
ogy to available inactive rhodopsin structures (Fig. 7A). A
model of the activated receptor (Fig. 7B) was obtained by
an expansion of the 7TM bundle, allowing the docking of
one molecule of the peptide. For these modeling proce-
dures, the alignment of the sequences in the 7TM bundle
and extramembrane domains to the rhodopsin structure
was made using the scheme shown in Figure 3 (249).
A) BINDING-RELATED RESIDUES. Binding assays using ra-
diolabeled ANG II or peptide analogs, and cloned AT1
receptors heterologously expressed in cultured cells, al-
lowed identification of the following binding-related resi-
dues (Fig. 7, B and C): 1) the ANG II COOH-terminal
carboxylate group is neutralized by the positive charge of
the receptor’s helix V Lys199A(512) (94, 111, 183, 195, 302,
303); 2) the peptide’s Tyr4 side chain binds at the recep-
tor’s Asn111A(325) (55); 3) the receptor’s Ser105A(319) is re-
quired for ANG II binding (78); 4) ANG II’s His6 and Phe8
side chains are in proximity to the receptor’s His256A(621)
and Phe259A(624) side chains (82, 195, 196); 5) the peptide’s
Arg2 guanidinium group interacts either with the recep-
tor’s Asp281A(712) (53) or Asp278A(709) side chain (94) {this
discrepancy seems to be due to the fact that different
ligands (ANG II or [Sar1,Leu8]-ANG II) were used in the
two studies, as discussed in sect. IIID1}; 6) the NH2-termi-
nal half of the EC-2 loop, including residues Val179A(469)
(94) and His183A(473) (53, 129, 303), is involved in ANG II
binding; 7) Lys101A(316), located at the extracellular end of
helix III, is important for binding (94, 183); 8) other resi-
dues involved in agonist binding are the Nt domain
Arg23A(105) (249), His24A(106), Tyr26A(108), and Ile27A(109) (94)
as well as the EC-1 loop Thr88A(238) (42) and Tyr92A(268)
(42, 94).
Besides site-mutation studies, structures of AGPCRs
have been analyzed by two indirect procedures: the sub-
stituted-cysteine accessibility method (16, 120, 176, 181)
and the methionine proximity assay (36, 154). In these
methods, residues are replaced by Cys and Met, and their
relative positions in the three-dimensional structure of
the receptors are defined as a function of kinetic param-
eters determined with Cys-specific reactants and by
means of photoaffinity labeling, using (in the case of the
AT1 receptor) ANG II analogs with benzophenone resi-
dues in position 8 (36).
The relative location (inside or outside the structure)
of residues along the sequences of helices was estimated
in many AGPCRs from cysteine accessibility results (16).
Also, movements of helices upon AT1 receptor activation,
as denoted by change in accessibility of strategically
placed Cys residues, was studied by Miura and Karnik
(176) and Miura et al. (181). A drawback linked to the Cys
accessibility method is that this residue is revealed by
bulky reagents. Because rhodopsin structures (151, 221)
FIG. 6. Structure of rhodopsin 7TM bundle showing residue posi-
tions identified according to degree of residue conservation. Within the
limits indicated for the membrane bilayer, only internal positions (point-
ing to the structure central cavity) are shown. Dark blue, variable
internal positions (EV boxes 23 and 33); orange, internal positions with
intermediate values of residue variation (EV boxes 12 and 22); red, very
conserved internal positions (EV box 11); green, variable extramem-
brane positions; light blue, very variable extramembrane positions.
572 OLIVEIRA, COSTA-NETO, NAKAIE, SCHREIER, SHIMUTA, AND PAIVA
Physiol Rev • VOL 87 • APRIL 2007 • www.prv.org
have an EC-2 loop interacting with the extracellular
halves of helices and closing the extracellular mouth of
the 7TM bundle central cavity, even small conformational
changes, such as those produced by mildly bulky re-
agents, might artificially change the relative position of
that loop and thus the accessibility of helices.
The Met-proximity assay also has limitations. To ap-
ply this method to AT1 receptors, the ANG II’s Phe
8
residue is replaced by a bulky moiety that is likely to
interfere with the role of this agonist’s aromatic residue to
induce receptor activation (178) and with the formation of
the salt bridge between the agonist’s COOH-terminal car-
boxylate group and the receptor’s helix V Lys199A(512) side
chain (53, 94, 111, 303). As a consequence, the obtained
results were contradictory. Against results from other
laboratories (53, 94, 111, 302, 303), a different geometry
for the ANG II binding site was described in which very
conserved AGPCR residues [Phe249A(614), Trp253A(618),
Asn294A(725), and Asn295A(726)], but not the specific
Lys199A(512) and Asp281A(712) residues, are claimed to be
involved in peptide binding (36).
B) RESIDUES PARTICIPATING IN RECEPTOR ACTIVATION. ANG II
structure-activity studies showed that the peptide’s Phe8
aromatic side chain is essential for triggering the response
by interacting with the receptor’s His256A(621) (178) (Fig.
7). Aromaticity and residue size in the ANG II position 4
side chain also appear to be important for activating the
receptor, possibly by interaction with the receptor’s
Asn111A(325). In addition, experiments with Lys199A(512) re-
ceptor mutants show that this residue can modulate the
effect of the His256A(621) side chain on receptor binding.
Whereas the H256A(621)A mutation does not affect bind-
ing, the loss of affinity of the [K199A(512)A;H256A(621)A]
double mutant is significantly larger than that of the
K199A(512)A mutant (196), suggesting that, in the AT1
structure, the Lys199A (512) ammonium group is able to
keep the His256A(621) imidazole ring at a specific position,
perhaps by forming an intramolecular hydrogen bond.
This interaction might not contribute to ligand-receptor
affinity (303), but could be important to form a more
productive receptor-agonist binding mode. This might in-
volve a relay-like structure consisting of ANG II’s COOH-
terminal carboxylate, the receptor’s Lys199A(512) ammo-
nium group, and the His256A(621) imidazole ring (82, 195).
B. Receptor Activation
AGPCR activation has been associated with a transi-
tion of the receptor’s structure from a constrained inac-
tive to an expanded active state (146, 149), in contrast to
inactivation by binding of nonpeptide antagonists which
drive a receptor to a more constrained inactive form (253,
294).
FIG. 7. A: model of the inactive AT1 receptor. The residues closing the extracellular locus (top right) and making bonds at the cytosolic ends
(bottom) are shown in orange. The EC-2 loop hairpin is shown in red. The salt bridge between the EC-2 loop’s Glu176A(464) and helix VI’s His256A(621)
is shown in green. B: model of activated AT1 receptor. The agonist site is at the top of the figure, with the ANG II molecule in magenta. Aromatic
residues involved in the activation mechanism are shown in green in the middle of the structure. Bonds between the cytosolic ends (residues in
orange) are dissociated. C: the agonist site. Peptide residues are identified by the one-letter code. See binding of helix V’s Lys199A(512) to the peptide’s
COOH-terminal carboxylate group and of helix VII’s Asp281A(712) to the peptide’s R2, at the middle left and top right (extracellular locus) of the figure,
respectively.
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Physiological receptor activation is triggered by ago-
nist binding (297), whereas constitutive receptor activa-
tion occurs in the absence of agonistic stimulus by side
chain mutations and other modifications of the AGPCR
structure (225).
1. Activation of rhodopsin
Activation of rhodopsin is seen as an expansion of
the structure. Figure 8A shows that the more likely site of
the 7TM bundle structure which may allow this expan-
sion, without the breakage of covalent bonds, is that
between two blocks of structure: a (helices I–V) and b
(helices VI and VII). Inside the block a helices, helix V also
moves in relation to helix III during activation (21, 224).
Functionally, ground state rhodopsin has a compressed
7TM bundle structure with an 11-cis-retinal moiety linked
to helix VII’s Lys296R(723) by a Schiff bond (151, 221, 254)
(Fig. 8B, 1). Light absorption causes retinal isomerization
to an all-trans-form (296), followed by slight modifica-
tions of the rhodopsin structure, probably limited to the
retinal pocket (150, 254). In a late stage, this effect can
spread over the structure giving rise to an equilibrium
between metarhodopsins I (MI) and II (MII), the latter
being the fully active form (112) that triggers transducin
coupling and other cytosolic events (168, 244). The acti-
vation of rhodopsin can be approached by following the
structural features relative to three states.
1) The first is the inactive state, containing important
interactions such as those involving the retinal Schiff base
and helix III’s Glu113R(318) (Fig. 8B, 1); the EC-2 loop’s
Glu181R(464) and helix VI’s Tyr268R(621) (151) (Fig. 8B, 2);
the helix III’s Arg135R(340) and helix VI’s Glu247R(600) (Fig.
8B, 3); and the VII-VIII bend’s Tyr306R(734) and helix VIII’s
Phe313R(810) (Fig. 8B, 4).
2) The second state is the MI form, in which the
bridge between the Schiff base and Glu113R(318) (Fig. 8B,
1) is ruptured and the counterion function exerted by this
residue is transferred to Glu181R(464) (243) (Fig. 8C, 5).
These modifications lead to the release of the Tyr268R(621)
residue and consequently of the extracellular third of
helix VI.
3) The third state is the MII form, produced by all-
trans-retinal contacts with aromatic side chains in the
middle of the 7TM bundle: helix VI’s Trp265R(618) and
Tyr268R(621), and helix III’s Trp126R(331) (137, 157) (Fig. 8C,
6). As a consequence of change in these residues’ posi-
tions, bonds between cytosolic ends of rhodopsin are
ruptured (Fig. 8C, 7 and 8) leading to expansion (170) and
activation of the receptor.
2. Physiological activation of AGPCRs and
AT1 receptors
The high variability of residues in the AGPCR agonist
binding sites (Fig. 6) reflects the heterogeneity of ligand
specificities. In general, the locations and dimensions of
the sites may differ according to size of the ligands. For
small molecules with retinal-like dimensions, such as bio-
amines, prostanoids, phospholipids, purines, and small
FIG. 8. The 7TM bundle of rhodopsin structure (151) is divided into two blocks: a (helices I–V) and b (TM helices VI and VII, and the cytosolic
helix VIII), shown in blue and light blue, respectively. The retinal and the hairpin in EC-2 loop are shown in magenta and red, respectively, whereas
residues involved in specific bonds [LysR(723), GluR(318),GluR(464), TyrR(621), ArgR(340) and GluR(600)] are shown in orange. Aromatic residues placed
at the middle of the 7TM bundle are shown in green. A: cross-section of the structure showing blocks a and b. B: inactive rhodopsin.
Retinal-helix-VII’s Lys(723) Schiff base makes a bond with helix III’s Glu(318) (1). Number 2 indicates hydrogen bond between EC-2 loop’s Glu(464)
and helix VI’s Tyr(621). At the bottom of the figure, two bonds are shown between helix III’s Arg(340) and helix VI’s Glu(600) (3) and between the
aromatic rings of the VII-VIII bend’s Tyr(734) and helix VIII’s Phe(810) (4). C: a model mimicking active rhodopsin (MII form) displaying the
all-trans-retinal with the Schiff base making a bond (5) with the EC-2 loop’s hairpin Glu(464). The all-trans-retinal is in contact (6) with the cluster
of aromatic residues. The bonds between cytosolic ends Arg(340)-Glu(600) (7) and Tyr(734)-Phe(810) (8), present in the inactive structure, are now
broken.
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peptides, the binding sites overlap entirely the rhodopsin
retinal pocket (29, 205). For larger ligands, e.g., peptides
(43, 69, 94, 116), melanocortin (159, 210), and glycopro-
tein hormones (52, 153, 293), the receptor-agonist inter-
action also involves positions in the extracellular seg-
ments of the receptor structure.
A) AGONIST BINDING AND ACTIVATION. ANG II binding to the
AT1 receptor, leading to its activation, is likely to be a
two-step process as suggested by studies of Le et al. (145)
and Feng et al. (56). The first step involves binding of
the peptide’s COOH-terminal segment (Tyr4-Ile5-His6-
Pro7-Phe8) at the retinal-like locus inside the 7TM bundle
central cavity, oriented by a salt bridge between the pep-
tide’s COOH-terminal carboxylate and the receptor’s
Lys199A(512) side chain (Fig. 7C, left). This binding, respon-
sible for the basal agonistic activity, would lead to expan-
sion of the 7TM bundle structure thus enlarging the space
between the EC-2 loop’s hairpin turn and helices I, II, VI,
and VII (Fig. 7C, right). For the interaction of its NH2
terminus (Asp1-Arg2) with AT1 receptor (second step of
binding), the ANG II molecule should bend at the level of
Val3-Tyr4 so that the Arg2’s guanidinium group would be
at binding distance from the receptor’s Asp278A(709) and
Asp281A(712) side chains (Fig. 7B, top). By completing its
interaction at the extracellular space between the EC-1,
EC-3 loops, and the Nt domain, the peptide would open
this space, favoring the separation of blocks a and b
initiated at the 7TM bundle.
AGPCR activation due to agonist binding is to be
compared with the mechanism triggered by retinal
isomerization in rhodopsin, leading to MI formation (Fig.
8). Agonist binding could exert pressure on the receptor’s
retinal-like locus, pushing aside the 7TM bundle helices.
The possibility of a role of aromatic residues on triggering
AGPCR activation was raised by the higher density of
these residues in the extracellular half of the receptor’s
7TM bundle, flanking the limits of the agonist site (118,
209). As this site comprises variable positions (Fig. 6),
activation in different AGPCRs may not be like that de-
scribed above for rhodopsin, namely, breakage of the
bond between EC-2 loop’s Glu181R(464) and helix VI’s
Tyr268R(621) (Fig. 8), being specific for receptor classes and
performed by different residues at different locations of
that site.
In AT1 receptor activation, a role of aromatic side
chains at the receptor and at the agonist in pushing the
structure towards an expanded form is observed. For
instance, ANG II’s Phe8 and Tyr4 (and His6) aromatic side
chains are involved in receptor activation (70, 178, 247)
through interactions with helix V’s Phe204A(517), helix VI’s
Phe249A(614), Trp253A(618), His256A(621) and Phe259A(624), and
helix VII’s Tyr292A(723) side chains (82, 175, 178, 195, 196)
(Fig. 7B).
Interestingly, the AT1 receptor, like rhodopsin, has an
EC-2 loop hairpin’s residue, Glu173A(464), which in the
inactive receptor model (Fig. 7A) is supposed to make a
salt bridge with helix VI’s His256A(621) side chain. This
could be broken upon receptor activation by agonist bind-
ing, thus mimicking the mechanism for formation of the
rhodopsin MI state. Also the disulfide bridge [Cys101A(315)-
Cys180A(470)] between EC-2 and the top of helix III (Figs. 2,
3, and 8) could be broken in the course of this mechanism,
thus supporting the hypothesis of a potential role which
has been attributed to this bond in AT1 receptors. Previ-
ously proposed by Pederson and Ross (228), Ohyama et
al. (200), and Karnik et al. (128) to regulate the activation
of these receptors, but mainly to be vital to keep the 7TM
bundle structure, the Cys101A(315)-Cys180A(470) disulfide
bridge has now been recognized, based on solid mutagen-
esis experiments, as an important factor to stabilize the
inactive state of C5a receptors (136).
The signal started at the agonist site level (extracel-
lular half of the structure) is transmitted along the AGPCR
7TM bundle by changes in receptor structure which in
rhodopsin are related to the formation of the fully active
MII state. In AGPCRs, this mechanism might follow a
pathway along the central cavity of the 7TM bundle struc-
ture (agonist-site-interface-main-site) involving positions
displaying a gradient of residue conservation (Fig. 6).
Signaling would start at the agonist site by different re-
ceptor-class-specific (agonist-specific) mechanisms but
should converge to a single receptor-family-specific path-
way at the cytosolic side of the 7TM bundle.
Translation and rotation of 7TM helices have been
proposed to occur during AGPCR activation. In AT1 re-
ceptors, movements of helix II (176), helix VII (25), and
helices II and VII (180, 181) have been observed. Nikifo-
rovich et al. (193) have proposed a mechanism of exten-
sive mobilization of the whole helix IV as a result of
constitutive activation of AT1 receptors elicited by muta-
tion in the helix III residue Asn111A(325) and adjacent res-
idues in the three-dimensional structure. Applied to the
physiological activation of AGPCRs, this mechanism
would be an additional step in the scheme discussed in
this and in the following sections.
B) EVENTS AT THE 7TM BUNDLE CYTOSOLIC ENDS. The activa-
tion of rhodopsin initiated at the 7TM bundle retinal site
leads ultimately to the dissociation of bonds between the
cytosolic ends of transmembrane helices, such as the
Arg135R(340), Glu247R(600), and Tyr306R(734)-Phe313R(810)
bonds shown in Figure 8B (7 and 8, respectively), which
stabilize the receptors’ inactive forms (151).
Many studies on the activation and inactivation of
AGPCRs due to mutations on residue positions of 7TM
cytosolic ends (see Table D in the supplemental material)
reveal that these mechanisms are mainly controlled by
interactions between conserved positions (340), (343) and
(344) of helix III, the conserved position (810) of helix
VIII, the conserved position (734) of the VII-VIII bend, and
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the variable positions (600), (603), (604), and (606) of
helix VI (see Figs. 2 and 3 for identification of positions).
In rhodopsin, the variable cytosolic half of helix VI
seems to work like a stalk holding the inactive form of
opsin. Thus Glu247R(600), Val250R(603), and Thr251R(604) inter-
act with helix III’s Arg135R(340), Val138R(343), and Val139R(344)
(Fig. 9, green spheres), keeping together blocks a and b of
the 7TM structure. In many AGPCRs, mutations at these
positions lead to activation (see references in the supple-
mental material Table D). On the other hand, helix VI
residues of Lys248R(601), Glu249R(602), and Ile253R(606), that
in rhodopsin’s structure are seen pointing outside or to
helices VII and VIII (Fig. 9, blue spheres), can make
interactions with these helices and thus favor receptor
activation. Mutations at position (606) of AGPCRs lead to
inactivation of receptors (see references in the supple-
mental material Table D).
A large residue variation observed in helix VI posi-
tions (600), (603), (604), and (606) of all AGPCRs suggests
variable strength in the interactions between 7TM cyto-
solic ends, and thus of activation and inactivation pat-
terns in the different classes of these receptors. Indeed, in
opsins and a few other receptor classes (25% of the
AGPCRs) for which position (600) contains Glu, the inac-
tive form is stabilized by a salt bridge (15) (Fig. 9). An
electrostatic bond between helix III’s Arg(340) and Glu-
(Asp) residues in other internal positions of helix VI, such
as (603) and (604), might produce a similar effect. In fact,
when Glu or Asp is introduced in positions (600) and
(604) of serotonin 5-HT6 (138) and mu-opioid (101) recep-
tors, these proteins are driven from wild-type constitu-
tively activated to inactive forms.
Some positions placed externally such as those of the
EC-2 loop (red spheres in Fig. 9) are involved in AGPCR
phosphorylation and G protein coupling mechanisms. The
same role can be recognized for external positions of
helix VI cytosolic end and helix VIII (not indicated in Fig.
9) (see references in the supplemental material Table D
for the respective cytosolic ends).
In AT1 receptors, position 235
A(600) is occupied by
Asn, whereas positions 238A(603) and 239A(604) bear Ile
and Phe, respectively (Fig. 7, A and B). N235A(600)A
mutation resulted in a slight increase of IP formation.
Mutations carried out at positions 238A(603) and, mainly,
239A(604) revealed that replacement of Phe239A(604) with
polar residues had relatively minor effects on receptor
responses, but its replacement by Asp or by positively
charged residues reduced or significantly increased these
responses, respectively (305). As receptor activation is
linked to the breakage of bonds between helices III and
VI, one may suppose that positive and negative charges at
helix VI’s position 239A(604) are repelled and attracted,
respectively, by the positively charged Arg126A(340) side
chain (Fig. 7, A and B). As helix VI Asn235A(600) is able to
form only a weaker hydrogen bond with helix III
Arg126(340), the dissociation of helices III and VI upon
N235A(600)A mutation is less sensitive to produce consti-
tutive activation than the breakage of a homologous
strong Glu(600)[Asp(600)]-Arg(340) salt bond of amine recep-
tors and other AGPCRs. Similar mutations of Ile238A(603)
led to inconclusive results (305) due perhaps to the fact
that this position is not so frontally located in relation to
helix III as position 239A(604). In consonance with this
interpretation, mutation on positions of Asp236A(601) and
Asp237A(602) led to AT1 receptor inactivation and G protein
uncoupling (305) or reduction of phosphorylation (202),
findings that are consistent with the accessibility of those
two positions revealed in the modeled structure of Fig-
ures 7A and 9.
Besides the interactions between the cytosolic ends
of helices III and VI, the inactive form of rhodopsin seems
to be held by a bond between the conserved Tyr306R(734)
and Phe313R(810) side chains (Fig. 9, right and bottom)
(64), indicating that upon activation this bond is broken,
releasing the cytosolic helix VIII from interactions with
FIG. 9. The cytosolic ends of inactive rhodopsin showing: 1) helix
III positions 340, 343, and 344 and helix VI positions 600, 603, and 604,
facing each other (green spheres); 2) the external positions of helix III
and IC-2 loop (red spheres); and 3) the positions of helices II, VI, VII, and
VIII facing each other (blue spheres). A salt bridge between helix III’s
Arg135R(340) and Glu247R(600) and an aromatic interaction between the
side chains of the VI–VII bend’s Tyr306R(734) and helix VIII’s Phe313R(810)
are shown in orange. Blocks a and b (see Fig. 8) are shown in blue and
light blue, respectively.
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the 7TM bundle structure. A similar condition is found in
other AGPCRs, such as the 5-HT(2C) receptor (242).
In short, two very conserved residues [Arg(340) and
Tyr(734)] in the cytosolic ends of AGPCR 7TM bundle
structure can be used as referential positions to orient the
interpretation of postactivation cytosolic events (Fig. 9).
It is possible to speculate that activation may be uniform
or not depending on whether the structure expansion
attains these two spots simultaneously or separately, re-
spectively. In the former event, the two bonds in the
cytosolic ends of the rhodopsin [the bond between
Tyr306R(734) and Phe313R(810) or the bond between
Arg135R(340) and Glu247R(600) at the right or left of Fig. 9,
respectively] are broken at the same time, and the struc-
ture is expanded uniformly. In the latter event, one of the
two bonds of the rhodopsin structure could be broken
first, thus contributing to change the relative orientation
of the centrally positioned helix VI, and destabilize the
interactions of this helix with the other side of the struc-
ture.
The ambivalence of this mechanism of signal trans-
duction can have important consequences. The orienta-
tion of the signal towards one cytosolic end of the 7TM
bundle could be dictated by different factors such as, for
instance, specific effects due to the binding of agonist side
chains to the agonist site (see Refs. 105, 198, 281 for AT1
receptors and Ref. 20 for rhodopsin). This would control
a mechanism of selective receptor activation to elicit
preferentially either G protein coupling or another post-
receptor activation event such as phosphorylation, arres-
tin binding, and internalization. Examples illustrating this
point are shown and discussed in section III, C1 and D3.
3. Constitutive activation
A) AGPCR IN GENERAL. We shall limit our analysis on
constitutive activation of AGPCRs (225) to the mecha-
nisms linked to residue mutations in the receptor’s 7TM
bundle and adjacent extramembrane segments. In these
regions of the receptor structure, one can observe (Fig. 6)
1) a high residue variation in the agonist site (residue
positions of Fig. 5’s EV boxes 23 and 33) and in the central
part of the bundle (residue positions of Fig. 5’s EV box
22), and 2) a high residue conservation in the internal
cytosolic half of the bundle central cavity (residue posi-
tions of Fig. 5’s EV boxes 11, 12, and 22) except the helix
VI (residue positions of Fig. 5’s EV boxes 23 and 33). Thus
the constitutive activation due to mutations in the extra-
cellular and central part of the AGPCR structure is spe-
cific for types of receptors (or groups of a few different
types), whereas in the 7TM bundle cytosolic ends, the
same process has a common component site on positions
of all helices but helix VI and a type-specific component
sited in helix VI positions.
As examples to illustrate the problem, some consti-
tutive activation events in AGPCRs, due to residue muta-
tions in the extracellular side and middle of helices, are
described below.
1) Rhodopsin is activated by mutation of the EC-2
loop hairpin Glu113R(318) residue which stabilizes Schiff
base positive charge, or of positions in helix II Gly90R(231),
helix V Phe212R(517), helix VI Met258R(610), Phe262R(614),
Trp265R(618), and Tyr269R(621) which make bonds at other
parts of the opsin-retinal interface (85, 137, 157, 261, 268)
(Fig. 8). Due to these facts, the apoprotein form of rho-
dopsin is also constitutively activated (259).
2) AGPCRs with mutations of bulky and mainly aro-
matic residues are constitutively activated, for instance,
Trp256G(618)Phe mutation in bradykinin B2 receptors
(160).
3) Besides AT1 receptors, mutation of Asn residue in
helix III position (325) can give rise to constitutive acti-
vation of bradykinin B2 (160) and cysteinyl-leukotriene
(48) receptors.
4) Glycoprotein hormone (follicle stimulating hor-
mone, thyroid stimulating hormone, and lutropin-cho-
riogonadotropic hormone) receptors are constitutively
activated by Asp(614) mutation and other mutations at
neighbor residues in helix VI and helices II and VII [polar
cluster positions (224), (725) and (726)] (7, 8, 171, 276,
290).
5) Mutations on helix V Ser204G(513), Ser207G(516), and
probably Ser203G(512) to Ala, all of them placed in the
agonist pocket of 2-adrenergic receptors, also lead to
constitutive activation (119).
Constitutive activation due to mutational events in
cytosolic ends of AGPCRs are discussed in detail in sec-
tion III, B2a and D3.
B) AT1 RECEPTORS. Constitutive activation of AT1 recep-
tors has been elicited by single mutations on residues
located along the receptor central cavity such as helix III’s
Asn111A(325) (55, 77, 106, 165, 174, 195) and Asn111A(325)
surroundings in three-dimensional structure (193), helix
VI’s Ile245A(610) (174), helix VII’s Asn295A(726) (17, 55, 181),
and cytosolic helix VIII’s Leu305A(806) (55, 174, 223).
The N111A(325)G mutation drives the AT1 receptor to
a constitutive activated state by overcoming a barrier that
is normally imposed by the Asn111A(325) side chain (55, 77,
165, 195). Substitution of this Asn residue appears to
release the 7TM bundle structure from a steric effect,
rather than from a polar interaction with receptor helix
VII residues of Tyr292A(723) (77) or Asn295A(726) (17),
which keeps the 7TM helices compacted and the receptor
inactivated. This interpretation comes from the fact that
Asn111A(325) mutation to Gly was the most effective to
elicit activation (55).
Based on modeling and mutagenesis procedures, Ni-
kiforovich et al. (193) proposed a mechanism to elicit
constitutive activation on AT1 receptor by mutation in the
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position of Asn111A(325) and surroundings in both helices
III and IV. This mechanism would consist of a chain of
conformational changes along the transmembrane helix
III from Leu112A(326) to Tyr113A(327) to Phe117A(331), which
can be propagated to helix IV residues Ile152A(419) and
Met155A(422) leading to an expressive movement of this
helix as a whole and modifications in the structure of the
IC-2 loop.
A screening of a randomly mutated cDNA library of
AT1 receptors (223) allowed the identification of the fol-
lowing 7TM mutations linked to constitutive activation of
these receptors: F77A(227)Y, N111A(325)S, L112A(326)H,
L112A(326)F, L118A(332)H, I193A(506)K, L195A(508)P,
and L305A(806)Q. Except for positions (506), (508), and
(806), the other positions are in or close to the interface
between blocks a and b of the structure (Fig. 8A) and thus
might contribute to the association of these receptor sub-
domains on the inactivated form of receptors.
Constitutive activation of AT1 receptors has also
been associated with mutations on residues Leu262A(627)
and Leu265A(630) at the extracellular third of helix VI which
increased the receptor-mediated adenylate cyclase activ-
ity (40, 41). Residue mutations in the cytosolic ends of
AT1 receptors have led to constitutive activation as de-
scribed, for instance, by Gaborik et al. (66) for the DRY
motif Asp125A(339) (see the supplemental material Table D
for many other occurrences).
4. AT1 receptor inhibition
Specific mutagenesis studies (41, 53, 94) showed that
competitive antagonistic peptides, such as [Sar1,Leu8]-
ANG II, bind AT1 receptors in the same two-step fashion
observed with the natural ligand. A minor difference is
that [Sar1]-ANG II requires both the EC-3 loop’s
Asp278A(709) and Asp281A(712) side chains for binding,
whereas ANG II is more dependent on binding to
Asp281A(712) and to the Nt domain’s Arg
23A(105). The impli-
cation of this difference is further discussed with more
details in section IIID1.
AT1 receptor inhibition by losartan is surmountable
since it can be reversed by ANG II and follows a typical
competitive mechanism in which only EC50 values are
increased. In contrast, inhibition by losartan’s carboxy-
lated metabolite EXP3174 is insurmountable and charac-
terized by increased EC50 values and decrease of maxi-
mum effect (291). Other carboxylate-containing deriva-
tives, such as irbesartan (34) and candesartan (182), are
also insurmountable inhibitors (274, 291). It has been
proposed that this type of inhibition is dictated by a free
carboxylate connected to the nonpeptide compound’s im-
idazole ring that would interact with the receptor’s
Lys199A(512) (Fig. 8) leading to insurmountable inhibition
(61, 188, 197, 292, 294, 295). However, the insurmountable
inhibition is also regulated by the receptor’s Gln257A(622)
residue at the extracellular third of helix VI (274), which
allows for a different binding mode of inhibitors to the
receptor agonist site.
Whereas AT1 receptor residues such as Asp
281A(712),
at the EC-3 loop, are not required for losartan binding
(129), mutagenesis screening showed that binding in-
volves many residues along the 7TM bundle structure (17,
78, 107, 121, 129, 183, 195, 197, 230, 231, 253). After
binding at positions in the extracellular halves of helices
V and VI (retinal-like locus), losartan seems to follow a
binding pathway different from that of ANG II (Fig. 7).
Instead of bending to fit the receptor’s extracellular locus,
the antagonist molecule is extended along the 7TM bun-
dle central cavity, between helices III, VI, and VII, proba-
bly contacting residues in the middle of the 7TM bundle
position 111A(325) in helix III, positions 294A(725) and
295A(726) in helix VII, and attaining the limits of the
protein/cytosol interface [positions 300A(731) and
301A(732) in helix VII].
Interestingly, this type of nonpeptide binding mode
to AT1 receptors seems to correspond to the binding
modes to the same receptors of ANG II-like molecules
containing bulky side chains such as benzophenone resi-
dues instead of Phe at position 8 (36), or to the model of
ANG II docking to the receptor obtained from molecular
dynamics simulations monitored by energy-minimization
criteria (14).
Perhaps due to its special binding mode, losartan can
also block the constitutive activation produced by muta-
tions in the middle of the AT1 receptor’s helices III, VI,
and VII, and thus it may be considered an inverse agonist
(174) which can prevent the installation of the receptor’s
tachyphylactic state (241). New findings, however, have
shown that only insurmountable nonpeptide AT1 receptor
inhibitors such as EXP3174 and candesartan, but not
losartan, are in fact strong inverse agonists that neutralize
the constitutive activation caused by N111A(325)G,
N295A(726)S, and L305A(806)Q mutations (56).
C. Mechanisms Following Receptor Activation
1. Signal transduction
AGPCR activation propagates to the intracellular
side of the receptor causing dissociation of interactions
between the cytosolic ends of helices I-III and V-VIII.
Considering the high residue conservation in the cytosolic
half of the 7TM bundle central cavity (Fig. 6), this mech-
anism is likely to happen in many AGPCRs, including
ANG II receptors. Due to the expansion of the structure,
some cytosolic ends of the receptor become accessible
for coupling to cytosolic proteins (170), triggering recep-
tor postactivation events such as G protein coupling,
phosphorylation, arrestin binding, internalization, and
binding to other factors.
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The various states assumed by AGPCRs to elicit dif-
ferent postactivation events seem to be interdependent
and interconvertible (12, 54, 124, 140, 167, 229, 280, 298)
and require the simultaneous participation of all receptor
cytosolic ends (189, 304).
The cytosolic ends of AGPCR structure can then be
coupled to G protein, phosphorylated by specific kinases,
bound to arrestin or be internalized via dynamin- and
clathrin-dependent coated-pit vesicles (80, 148). In AT1
receptors, the pathway of G protein coupling is indepen-
dent of that of arrestins and occurs only in response to
ANG II aromatic (Tyr4 and Phe8) and Arg2 side chains (45,
54, 97, 173). Arrestin pathway leads to autonomous cyto-
solic events (257, 258). In the case of rhodopsin, it has
also been shown that the structure of the agonist can
remotely regulate the selection of cytosolic events. In
fact, modifications in the structure of retinal can turn this
molecule into a partial agonist that is able to give rise to
a shorter and less intense activated state of this opsin
(20).
The two most known events following activation of
AGPCRs, namely, G protein coupling and arrestin binding,
are discussed in section III, C2 and C3. However, only
molecular features of these events, which can be related
to the mechanism of receptor activation, were selected
for this discussion. In this context, oligomerization of
AGPCRs shall not be the focus, since it is yet not clear
whether this event is systematically due to previous ago-
nist binding and is related to receptor activation (28, 117,
233, 277).
2. G protein activation
G protein activation mediated by activated GPCRs
causes GDP release from the G chain nucleotide site,
GTP association, and consequent dissociation of G
chains from the G complex (37, 142, 272). Kinetic anal-
yses in which rhodopsin’s mutants were used to activate
wild-type transducin heterotrimers showed at least two
categories of results (50, 51, 162). First, mutations in the
DRY motif of helix III and deletion in the EC-2 loop
impaired initial coupling of rhodopsin to the G-GDP
complex. Second, deletions in the IC-3 loop and in the
cytosolic end of helix VI, replacement of the sequence in
the IC-2 loop and mutations in NH2-terminal positions of
helix VIII, impaired GDP dissociation.
For nonopsin AGPCRs, the regions involved in G
protein coupling are the same as those described for
rhodopsin: Asp-Arg of the DRY motif of helix III, the IC-2
loop middle, the IC-3 loop and beginning of helix VI, and
the cytosolic helix VIII (see the supplemental material
Table D).
An important problem about receptor-G protein cou-
pling is whether to analyze it by a chemical equilibrium or
by a kinetic approach. According to chemical equilibrium
criteria, the interaction between biological molecules is
driven by specific binding sites, and no G-specific sites in
the structure of receptors have been described. Neverthe-
less, G protein coupling to GPCRs occurs in practice, and
two other approaches for this interaction should be con-
sidered.
1) No direct contact exists, and G protein coupling is
driven by external environmental factors (88, 167) or by
special adaptors providing specific connection between
the different receptors and G chain types. The existence
of a long list of little characterized proteins with the
ability to bind G protein chains and GPCRs (24, 65, 190,
235) favors this possibility.
2) G protein coupling to GPCRs can be interpreted by
kinetic criteria according to mechanisms found in intrin-
sically unfolded protein structures (47). Being loose or
dissociated from the main folds, these structures can
adapt themselves to interactions with different structures
and thus play roles such as that observed in the case of
the activation of viral transcription factor (123). This
mechanism is supported by the fact that the process is
promiscuous (86, 88, 95, 139, 287), occurs at plasma mem-
brane compartments, and can be associated with rafts
(141, 265). Also, it has been linked to loosely folded
peripheral regions of the G protein and GPCR structures
which are not integrated in the basic folds, such as the
cytosolic ends of AGPCRs and the NH2-terminal and
COOH-terminal tails of G and G chains. All these struc-
tures have to be anchored to and clustered at a same
region of the membrane, thus forming a compartment, to
elicit function (37, 142, 272). G protein coupling is transi-
tory, since it requires fast molecular contacts aiming at an
easier dissociation of GDP from G chain nucleotide sites
followed by GTP association. Thus the receptor is imme-
diately released and may be reutilized in a new cycle, and
G chain complexes are released for specific functions.
Some models for rhodopsin coupling to transducin
proposed along the last 10 years (11, 35, 62, 89, 133–135,
204, 206) are subject to questions since, by ignoring the
promiscuity of the G protein-receptor interaction, they
were proposed as if all criteria for chemical equilibrium
were fully satisfied.
3. Arrestin binding
Arrestins are adaptors able to perform biphasic bind-
ing to activated AGPCRs and to clathrin (148), thus pro-
viding conditions for internalization of these receptors via
the classical mechanism of coated-pit vesicles (60).
Among the four types of arrestins known, two (1 and
4) are in visual rod and cone cells and regulate opsins.
Arrestins 2 and 3 (or -arrestins 1 and 2) are present in
many other cells and regulate other GPCRs (80, 148).
Arrestin structures consist of two lobes with seven sand-
wiched -strands connected by interactions of internal
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polar or hydrophobic residue side chains. Interactions
involving the arrestin COOH- and NH2-terminal segments
are the key elements that keep the protein structure
closed under an inactive form (72, 83, 93, 220).
Due to this structural feature, binding of arrestins to
AGPCRs is biphasic (73, 219, 234, 237). The first step
follows protein kinase-mediated phosphorylation (155) of
Ser and Thr residues at the ends of the receptor’s COOH-
terminal domain (172, 219). In interacting with the so
incorporated phosphate groups, arrestins can have some
of their internal interactions broken, thus allowing the
expansion of their structures and high-affinity binding at
receptor regions whose conformation was changed by
agonist-mediated activation (44, 80, 132, 147, 219, 234,
237). Under special conditions, the first step of arrestin
binding to AGPCR phosphate groups can be omitted, as
for instance when a different splicing form of this protein
(p44) is expressed (219, 220, 237).
In consonance with the previously discussed mecha-
nism of AGPCR activation (see sect. IIIB), this arrestin
binding mechanism can emphasize a point already dis-
cussed above for G protein coupling (see sect. IIIC2).
Arrestin coupling to receptors has also to be analyzed by
kinetic approaches. In fact, for G proteins, only a few
arrestin types are known with the ability to couple many
different classes of receptors. In addition, coupling of
arrestins to receptor would have a main role of transito-
rily exposing areas of these proteins for more stable
binding to clathrin and formation of coated-pit vesicles
(60).
D. Overview of the AT1 Receptor
1. Activation in the 7TM bundle
Upon activation, disruption of bonds between helices
releases the AGPCR’s 7TM bundle from constraints, lead-
ing to expansion of the structure. Physiological activa-
tion, due to binding of full agonists, causes widespread
receptor expansion, whereas constitutive activation, due
to residue mutations at different sites of the 7TM bundle,
leads to different degrees of expansion. This assumption
is supported by the finding that ANG IV [ANG-(3O8)],
which has a negligible effect on the wild-type AT1 recep-
tor, is also, as well as ANG II, a bad agonist for the
D281A(712)A mutant (145), indicating that the interaction
of ANG II’s Arg2 with the receptor’s Asp281A(712) plays an
important role in the general binding. Also, [Sar1,Ile4,Ile8]-
ANG II, which is inactive on the wild-type receptor, elic-
ited a normal response by the constitutively active
N111A(325)G mutant (56, 181), indicating that ANG II’s
aromatic residues Tyr4 and Phe8 induce receptor activa-
tion mimicking the N111A(325) mutation’s effects (56).
The interaction between ANG II’s Arg2 and the EC-3
loop’s Asp281A(712) is important since, in the absence of
any of the two partners, the agonist-receptor complex can
only be formed at higher EC50 values. This finding could
be explained by assuming that the extracellular locus of
inactive AT1 receptor is closed by bonds between resi-
dues of the EC-3 loop [Asp278A(709) and Asp281A(712)] and
the Nt domain [Arg
23A(105) and His24A(106)] (Fig. 8). The
role of the Arg2-Asp281A(712) bond would be to break these
interactions, thus driving the opening of the extracellular
locus, a mechanism that is absent when ANG IV is the
ligand or the D281A(712)A mutant is the receptor.
The expansion resulting from the N111A(325)G mu-
tation seems not to be restricted to the 7TM bundle but
can attain the extracellular locus where it drives the
separation of the EC-3 loop from the Nt domain. Under
this condition, the activation of the N111A(325)G mutant
does not require the Arg2-Asp281A(712) interaction between
the peptide and receptor. This is confirmed by the fact
that ANG IV can activate a double N111A(325)G;
D281A(712)A mutant of AT1 receptor (145).
Additional features of the AT1 receptor extracellular
locus, such as the specific roles of the Asp278A(709) and
Asp281A(712) residues in agonist binding, can be recognized
when ANG II analogs with modifications in position 1 are
used as ligands. Both receptor’s Asp residues are involved
in the [Sar1]-ANG II binding, but only Asp281A(712) is im-
portant in the ANG II binding (53, 94). It was also reported
that the receptor’s Arg23A(105) residue is involved in the
binding of ANG II’s NH2-terminal end (probably of the
Asp1 side chain) but not when [Sar1]-ANG II is the ligand
(249). To explain these data, a scheme was built in which
two states of the AT1 receptor extracellular locus were
considered (Fig. 10). In state 1, the ANG II’s Asp1 and Arg2
bind to the receptor’s Arg23A(105) and Asp281A(512), respec-
tively. In state 2, the peptide’s NH2-terminal segment is
shifted towards the EC-3 loop so that the NH2-terminal
ammonium group now binds to the receptor’s Asp278A(709)
while the Arg2 side chain remains bound to the receptor’s
Asp281A(512) (structure I in Fig. 10). When the ligand is
[Sar1]-ANG II, state 2 is favored by the positively charged
Sar1 moving away from the receptor’s Nt domain and
binding to the EC-3 loop’s Asp278A(709) (249). As [Sar1]-
ANG II is the most potent ligand to produce the tachy-
phylactic state in AT1 receptors (211), it has been specu-
lated that this functional event is associated with confor-
mational state 2 of these receptors.
In summary, the first and second steps of ANG II
activation (Fig. 8) may mimic the constitutive activation
due to the N111A(325)G mutation (55, 77, 106, 165, 195).
The activation is propagated to the middle of the 7TM
structure and to its cytosolic half, where it could change
the arrangement of polar interactions, thus facilitating the
separations of blocks a and b (Fig. 8A). This effect would
be mimicked by mutations at these residues, especially
the N295A(726)S mutation in helix VII. In a final step, the
activation reaches the cytosolic ends of the 7TM bundle,
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resulting in dissociation of these structures. The muta-
tions at Tyr302A(734) and Phe309A(810), disrupting the bond
between them (see Ref. 242 for serotonin 2c receptors),
and at Leu305A(806), reported to cause constitutive activa-
tion (56, 174, 223), may also be interpreted as facilitating
the dissociation of the 7TM cytosolic ends.
Interestingly, AT2 receptors that were previously de-
scribed as constitutively activated under a wild-type form
(179), were shown to have binding ability independent of
ANG II’s aromatic or Arg2 side chains. It appears that
these receptors could be compared with Asn111A(325) mu-
tants of the AT1 receptor. In addition, AT2 receptors have
different residues at the extracellular locus’s EC-3 loop
and Nt domains so as to allow the hypothesis that this site
could also be opened in agonist-free receptor forms.
2. The role of the cluster of polar residues:
the sodium site
AGPCRs have a cluster of conserved polar residues
(mostly belonging to EV boxes 11 and 12 of Fig. 5) in the
cytosolic half of the 7TM bundle central cavity consisting
of the following residues: Asn(130), Asp(224), Ser(329),
Asp(339), Asn(Ser)(725), Asn(Ser)(726), and Asn(729). They
are involved in signal transduction of practically all
AGPCRs (see mutation data in GPCRDB and tiny GRAP).
Some AGPCRs, such as opioid (232), 2-adrenergic
(156), dopamine D2 (269), neurotensin (166), and adeno-
sine (18) receptors, are regulated by sodium whose action
leads to decrease of receptor affinity for agonists without
interfering with antagonist binding (156). These effects
may be linked to the cation binding site located in the
middle and in the cytosolic sides of the 7TM bundle
central cavity shown in models built for dopamine D2
receptor (191), but which can be applied to other
AGPCRs, considering the conservation of the involved
residues. These residues [Asn(130), Asp(224), Ser(329),
Asn(Ser)(725), Asn(Ser)(726) and Asn(729)] are also found in
the list of AGPCR polar cluster residues, which allows us
to suggest that the effects due to sodium ions and the
effects linked to AGPCR polar cluster are interrelated.
Sodium ions do not alter substantially the affinity of
agonist binding to AT1 receptors (23), but strong cation-
mediated inhibitory effects on both constitutive and phys-
iological activations of these receptors have been re-
ported (56). As these receptors have all residues of the
polar cluster and consequently of the sodium site, it is
plausible to make an association between the cation-
mediated inhibitory effects on AT1 receptors and an AT1
facsimile of the site of Neve et al. (191) built for dopamine
D2 receptors.
The roles of the AGPCR polar cluster residues, in-
cluding those of the sodium site, should be crucial as long
as their replacements in many classes of receptors can
lead to so extreme conditions as signal abolition. If this is
so, how do you explain the fact that some natural replace-
ments of these residues in other receptors are not accom-
panied by function impairment? Many examples showing
these discrepancies are found in GPCRDB and tiny GRAP
mutation data, and some of them deserve to be shown
here for illustration.
1) The first experiments on the AT1 receptor helix II
showed that D74A(224)N mutation produced drastic de-
cay of IP formation (23), while D74A(224)Y and
D74A(224)H mutations had little effect on phosphorylase
activation but impaired largely the receptor internaliza-
tion (102). Paradoxically, the position of Asp(224) is occu-
pied by Asn in many functional AGPCRs such as opsins
(rhodopsins and visual blue or violet pigments) and re-
ceptors for chemokine, phospholipids, and other ligands.
2) N295A(726)S mutation in AT1 receptors usually
leads to constitutive activation (56, 181), whereas
N294A(725)A mutation at the adjacent position of the
same receptor impaired receptor activation (107). Asn
and Ser are frequently replaced by each one in positions
(725) and (726) of AGPCRs and are both absent in func-
tionally active opsins and olfactory receptors. Ala is found
in position (725) of many opsins and in position (726) of
some purinergic receptors.
3) S115A(329)A mutation in AT1 receptors (183) and
S(329)A mutation in 1-adrenergic receptors (33) were
FIG. 10. Two states (1 and 2) of the AT1 receptor extracellular locus
(see Fig. 8, top right). Upon binding ANG II, the receptor first attains
state 1, in which the Nt’s Arg
23A(105) and the EC-3 loop’s Asp281A(712)
residues contact the peptide’s D1 and R2, respectively. In a second step,
the complex relaxes to state 2, in which the receptor’s Nt domain is
dissociated from the peptide’s D1, which is left to contact the peptide’s
NH2-terminal NH3
 group or the receptor’s EC-3 loop Asp278A(709) residue
(condition I of state 2). Upon binding [Sar1]-ANG II, the receptor is
supposed to go directly to state 2 (condition II) as the Sar1 group moves
away from the receptor’s Nt domain towards the EC-3 loop’s Asp
278A(709)
residue.
ANG II AT1 RECEPTOR STRUCTURE AND ACTIVITY 581
Physiol Rev • VOL 87 • APRIL 2007 • www.prv.org
accompanied by IP formation decay without impairment
of agonist binding. Paradoxically, Ser(329) which is found
in many AGPCRs (amine and many peptide receptors) is
replaced in many functionally active receptors by Gly or
Glu (interleukin-8 and chemokine receptors), Thr (endo-
thelin receptors), Ala (opsins), Asp or Glu (olfactory re-
ceptors).
A straightforward way to circumvent these conflict-
ing events should go through some assumptions. The
mechanism of activation of AGPCRs can basically be
defined as an expansion of the 7TM bundle structure as
described in section IIIB (Fig. 8). There are all along the
7TM bundle structure many structural motifs that can
modulate the extent of AGPCR activation. The cluster of
polar residues in the middle and in the cytosolic sides of
the structure is one of these motifs. In the cluster, the
polar residues are interacting with each other giving rise
to certain configurations that can favor the active or the
inactive forms of AGPCRs. In this context, the modulation
by sodium ions is a special condition for some AGPCRs in
which the polar cluster acquired a configuration with
appropriate residues located in a such manner that the
formation of a cation site and modulation by specific
binding were allowed. In this case, sodium ions have
mostly been found to inhibit agonist binding in many
AGPCRs as well as IP formation in AT1 receptors (see
above).
It was shown in AT1 receptors that mutations in
residues of the polar cluster, including residues of the
sodium site, have effects on receptor function that are
more inhibited by the cation. For instance, the effects due
to the mutation in the position of Asn111A(325) of AT1
receptors is much less cation sensitive than mutations in
positions 295A(726) and 305A(806) of the same receptors
(56).
In the absence of sodium, and therefore under acti-
vating conditions, the organization of the polar residues
forming the binding site and its neighborhood should be
so as to facilitate the separation of blocks a and b and the
expansion of the 7TM bundle structure (Fig. 8). This
should be a special arrangement which, in the structure of
the AT1 receptor, depends on the Asn
295A(726) side chain.
Sodium binding at this site might bring the polar residues
together, thus inhibiting receptor activation. Mutations of
Asn295A(726) to other polar residues, such as Ser, should
lead to other loose arrangements of the sodium site resi-
dues allowing easier expansion and larger activation
when the cation is absent.
The existence of different configurations for the clus-
ter of polar residues in AGPCRs is embodied by models
describing the activation of different receptor classes. For
instance, a special arrangement of hydrogen bonds has
been considered in 5-HT2A receptors involving internal
polar residues of helix II Asp(224) and helix VII Asn(729).
Whereas an Asp-Asn mutation in helix II eliminated cou-
pling, interchanging the residues at the two positions by a
second mutation of Asn-Asp in helix VII restored receptor
function. These data suggest that these residues are adja-
cent in space and interact with each other (255). As AT1
receptor has both Asp74A(224) and helix VII Asn298A(729)
residues, a same arrangement of polar residues may be
postulated to exist in the cytosolic side of 7TM bundle
central cavity of these receptors. Even the mechanism of
Asn111A(325) binding to Tyr292A(723) postulated by Grob-
lewski et al. (76) might be involved in this context.
In glycoprotein thyroid stimulating hormone recep-
tors, the helix VI contains a conserved Asp instead of the
prevalent residue of Phe in the position (614), which is
supposed to make special arrangements in the AGPCR
common cluster of polar residues (290).
3. Events at the cytosolic domains
The classic pathway of cytosolic events triggered by
agonist-mediated activation of AGPCRs consists of G pro-
tein coupling and effector activation, followed by phos-
phorylation of the COOH-terminal Ser and Thr residues,
arrestin binding, and internalization (80, 148). In AT1 re-
ceptors, peptide binding leads to activation of Gq/11 pro-
teins and subsequently of phospholipase C, or to activa-
tion of protein Gi followed by regulation of cAMP levels
(12, 173, 260).
Ohtsu et al. (199) provided evidence that Rho/ROCK
activation through PYK2 and protein kinase C- is specif-
ically required for ANG II-induced migration of vascular
smooth muscle cells (VSMC) via JNK activation. Thus, in
addition to the cell migration, activation of Rho/ROCK
represents one of the key signal transduction pathways
originating from the VSMC AT1 receptor that mediates
pathophysiological functions of ANG II such as contrac-
tion mediated by G12/G13 (71), atherogenic gene expres-
sion mediated by Rho-kinase, MEK/ERK pathways (273),
and cardiovascular hypertrophy involving Rho-kinase and
NAD(P)H oxidase system (90, 301).
A pathway leading to internalization is also observed
(105, 198, 266, 279, 281). However, the assumption that
the receptor state linked to G protein coupling is a pre-
requisite step for phosphorylation-arrestin-binding-inter-
nalization is subject to question (97). In fact, it appears
that postactivation cytosolic events in AGPCRs do not
follow a simple rule but are regulated by an intricate
scheme, and the AT1 receptor might be used as a model to
analyze the events in AGPCR’s 7TM bundle structure in
view of the large number of available experimental data.
1) The pathway leading to AT1 receptor endocytosis
(38) seems to start with phosphorylation of Ct domain’s
Ser and Thr residues (104) and to be regulated by other
receptor regions such as helix VIII’s Leu316(817) and
Tyr319(820) (278) and the cytosolic end of helix VI
[Asp263(601)-Asp264(602)] (202).
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2) To allow G protein coupling, many residues on the
AT1 receptor cytosolic end structure are required, such as
Arg126(340) in helix III (54, 66, 201, 260, 299), Ile130(344) and
Met134(349) in the IC-2 loop (66, 260), Tyr215(528) in helix V
(103), Leu222(535) in the IC-3 loop (109, 144, 201),
Tyr292(723) in helix VII (161), and Tyr312(813), Phe313(814),
and Leu314(815) in helix VIII (248).
3) The pathway leading from receptor activation to G
protein coupling is initiated by ANG II binding, whereas
analogs devoid of aromatic rings (such as [Sar1,Ile4,Ile8]-
ANG II) lead to the internalization pathway (56, 97, 105,
181, 280, 298).
4) Constitutively activated N111(325)A(G), I245(610)T,
and L305(806)Q receptor mutants have been found located
in intracellular vesicles, differing from wild-type receptors
that are in the plasma membranes (174). Furthermore, the
N111(325)G mutant induced basal IP production that was
reverted by the inverse agonist EXP3174 but not by losar-
tan (181).
5) When stimulated by ANG II or [Sar1,Ile4,Ile8]-ANG
II, the N111(325)G mutant induces maximum IP re-
sponses and is internalized without increase of phosphor-
ylation (280).
The above results suggest a mechanism to select one
of the two main AT1 receptor postactivation pathways. G
protein coupling would occur when a larger expansion of
the AT1 bundle is caused by agonist binding, exposing
many residues in the cytosolic ends of this structure. This
condition is likely to occur by binding of agonists con-
taining aromatic side chains, and it could involve a large
separation of the ends of helical columns due to simulta-
neous breaking of bonds linking helix III to helix VI and
the VII-VIII bend to helix VIII as shown in Figure 9.
On the other hand, a phosphorylation-arrestin-inter-
nalization pathway may require only accessibility of the
receptor’s COOH-terminal domain for protein kinase ac-
tion and consequent initial binding of arrestins or other
factors. Nevertheless, this explanation contradicts find-
ings that constitutively activated AT1 receptors [such as
N111A(325)G mutants] can induce both pathways, G pro-
tein coupling and internalization, by a mechanism that is
independent of phosphorylation (280).
4. Conclusions
Irrespective of the amino acid residues found in the
middle of the 7TM central cavity (conserved positions in
Fig. 6) or even in the agonist site (variable positions in
Fig. 6), practically all AGPCRs can be physiologically
activated by a general mechanism compatible with that of
AT1 receptors proposed by Feng and co-workers (54, 56):
an initial two-step ANG II binding to the inactive receptor
retinal-like locus and adjacent extracellular loops leading
to a large structural rearrangement consistent with the
Asn111A(325) mutation effect, followed by breaking of in-
terhelix bonds leading to expansion of the 7TM bundle
and separation of its cytosolic ends.
The existence of a cluster of polar residues in the
middle of the 7TM bundle, forming or not a sodium bind-
ing site, could have been randomly developed during
evolution in some receptors that made early contact with
ions, and it should not be recognized as a rule in the basic
general mechanism of AGPCR signal transduction.
Two main pathways of cytosolic events have been
commonly observed. The first one involves an obligatory
G protein coupling step and is selected by the binding of
ANG II aromatic and/or NH2-terminal residues. A second
pathway that may be selected by binding of ANG analogs
devoid of aromatic or NH2-terminal residues leads di-
rectly to phosphorylation, arrestin binding, coated pit
formation, and internalization steps without a previous G
protein coupling event. The NH2-terminal residues of the
agonists ANG II and [Sar1]-ANG II seem to bind by two
distinct modes to the AT1 receptor extracellular site (Fig.
7). As the [Sar1]-ligand is the most potent molecule to
trigger tachyphylaxis in AT1 receptors, it was suggested
that its corresponding binding mode might be associated
with this special condition of receptors.
IV. FINAL REMARKS
Among other aspects of AGPCR function, the follow-
ing themes are or may be supposed to become targets for
current or future investigations.
A. Active Rhodopsin (AGPCR) Structures as a
Result of Probabilistic Analyses
Following the determination of the inactive rhodop-
sin structure there was an expectation that the structure
of activated rhodopsin and the entire functioning cycle of
this protein would also be determined. However, high-
resolution structures of activated rhodopsin could not be
obtained by crystallographic procedures, perhaps be-
cause this form of protein is not sufficiently stable (254).
This suggests that the study of rhodopsin and other
GPCRs requires a probabilistic approach in which acti-
vated receptors behave as unstable or fluctuating struc-
tures. Thus activation should not enable them to strongly
bind but rather to destabilize stable cytosolic proteins
such as GDP-G chain complexes and inactive forms of
arrestins. This would allow the onset of other mecha-
nisms such as GTP binding at an empty G nucleotide
site, kinase-mediated phosphorylation of receptor and ar-
restin binding to the receptor and clathrin, first steps of
known series of chain reactions occurring at the cytosol.
The nonexistence of specific binding sites to mediate
coupling of each GPCR to cytosolic proteins such as G
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chains and arrestins provides corroboration for the prob-
abilistic assumption.
B. The Extracellular Locus as a Site for
Cross-Talking Mechanisms
An extracellular locus in AT1 receptors (Fig. 7) was
postulated as a result of the finding that the receptor’s
Arg23A(105) residue contacts ANG II Asp1 (249), thus rais-
ing the possibility of an agonist-mediated mechanism di-
rected to the extracellular medium. The second disulfide
bond linking two walls of the extracellular locus of the
AT1 receptor (the distal segments of EC-3 loop and Nt
domain) also reinforces the same hypothesis, since in AT2
receptors the homologous disulfide bond was found to be
a regulator of dimerization (179). Interestingly, in AT1
receptors, the same bond was suggested to be involved in
a mechanism leading to stabilization of the extracellular
site structure (39).
C. The AT2 Receptor Is a Natural Constitutively
Activated Form of AGPCR
Although AT2 receptor sequences are similar to those
of the AT1 receptor (see the supplementary material Table
B), the functions of these types of ANG II receptors are
quite different. The AT2 receptor seems to be constitu-
tively activated to produce apoptosis (177) and, in this
respect, may be considered as an Asn111A(325) mutant of
the AT1 receptor (175). An inspection of the sequences of
the AT1 and AT2 receptors shows some subtle differences
that might be responsible for the dissimilar behavior of
these proteins.
1) The His256A(621) residue present at the extracellu-
lar third of the AT1 receptor’s helix VI, which might be
bound to the EC-2 loop favoring the inactive form of the
receptor, is displaced to position (622) in the AT2 recep-
tor, where it cannot play a similar role.
2) An Arg residue is found at the cytosolic COOH-
terminal tail [position (600)] of the AT2 receptor’s helix VI
which, as discussed above, would favor constitutive acti-
vation.
3) Asp(709) is absent in the EC-3 loop of the AT2
receptor, and an Asp(106) is found instead of the His24A(106)
at this position of the AT1 receptor Nt domain. These
differences suggest that the extracellular locus in the AT2
receptor is likely to be opened in agonist-free forms,
favoring constitutive activation.
D. The Cluster of Polar Residues: The Sodium Site
The fact is that all the mechanisms related to the
cluster of polar residues and sodium site are still nebu-
lous. Systematic and exhaustive research is needed. All
polar residues of the internal polar cluster of AGPCRs
(AT1 receptors included) have to be mutated and assayed
at different concentrations of sodium to test the regula-
tion of these ions (or of other ions) on effects produced
by the mutations. The first steps in this direction were
already given by Feng et al. (56) who revealed that AT1
receptor N111A(325)G and N295A(726)S or L305A(806)Q
mutations were less and more sensitive to sodium ions,
respectively, a condition which may a priori be inter-
preted as a function of the proximity of these residues to
the ion binding site.
V. SUMMARY
The most prevalent physiological effects of ANG II,
the main product of the renin-angiotensin system, are
mediated by the AT1 receptor, a rhodopsin-like AGPCR.
Numerous studies of the cardiovascular effects of syn-
thetic peptide analogs allowed a detailed mapping of ANG
II’s structural requirements for receptor binding and ac-
tivation, which were complemented by site-directed mu-
tagenesis studies on the AT1 receptor to investigate the
role of its structure in ligand binding, signal transduction,
phosphorylation, binding to arrestins, internalization, de-
sensitization, tachyphylaxis, and other properties. The
knowledge of the high-resolution structure of rhodopsin
allowed homology modeling of the AT1 receptor. The
models thus built and mutagenesis data indicate that
physiological (agonist binding) or constitutive (mutated
receptor) activation may involve different degrees of ex-
pansion of the receptor’s central cavity. Residues in ANG
II structure seem to control these conformational changes
and to dictate the type of cytosolic event elicited during
the activation: 1) agonist aromatic residues (Phe8 and
Tyr4) favor the coupling to G protein, and 2) absence of
these residues can favor a mechanism leading directly to
receptor internalization via phosphorylation by specific
kinases of the receptor’s COOH-terminal Ser and Thr
residues, arrestin binding, and clathrin-dependent coated-
pit vesicles. On the other hand, the NH2-terminal residues
of the agonists ANG II and [Sar1]-ANG II were found to
bind by two distinct modes to the AT1 receptor extracel-
lular site flanked by the COOH-terminal segments of the
EC-3 loop and the NH2-terminal domain. As the [Sar
1]-
ligand is the most potent molecule to trigger tachyphy-
laxis in AT1 receptors, it was suggested that its corre-
sponding binding mode might be associated with this
special condition of receptors.
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